These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12086391)

  • 1. Drug-eluting stents in the treatment of atherosclerotic coronary heart disease.
    Lemos PA; Regar E; Serruys PW
    Indian Heart J; 2002; 54(2):212-6. PubMed ID: 12086391
    [No Abstract]   [Full Text] [Related]  

  • 2. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peeling-off labels mounting evidence for benefit of drug-eluting stents with off-label use.
    Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2007 Nov; 50(21):2037-8. PubMed ID: 18021869
    [No Abstract]   [Full Text] [Related]  

  • 5. Modern strategies to prevent coronary restenosis.
    Chieffo A; Stankovic G; Colombo A
    Ital Heart J; 2002 Jun; 3 Suppl 4():9S-15S. PubMed ID: 12116826
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future.
    Leon MB; Bakhai A;
    Am Heart J; 2003 Oct; 146(4 Suppl):S13-7. PubMed ID: 14564301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left main coronary artery stenting: crossing the Rubicon.
    Alfonso F
    J Am Coll Cardiol; 2009 May; 53(19):1769-72. PubMed ID: 19422983
    [No Abstract]   [Full Text] [Related]  

  • 8. [Drug-eluting coronary stents].
    Fontos G
    Orv Hetil; 2006 Oct; 147(43):2059-66. PubMed ID: 17297752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial comment: which is the preferred drug-eluting stent?
    Brodie BR
    J Interv Cardiol; 2006 Feb; 19(1):39-42. PubMed ID: 16483338
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug-eluting stents: the panacea for restenosis?
    Lim MC
    Singapore Med J; 2004 Jul; 45(7):300-2. PubMed ID: 15221043
    [No Abstract]   [Full Text] [Related]  

  • 11. Early experiences and clinical implications of restenosis and drug-eluting stents: Part 2.
    Chong PH; Cheng JW
    Ann Pharmacother; 2004 May; 38(5):845-52. PubMed ID: 15039482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting stents: preventing restenosis.
    Slavin L; Chhabra A; Tobis JM
    Cardiol Rev; 2007; 15(1):1-12. PubMed ID: 17172878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus.
    Boyden TF; Nallamothu BK; Moscucci M; Chan PS; Grossman PM; Tsai TT; Chetcuti SJ; Bates ER; Gurm HS
    Am J Cardiol; 2007 May; 99(10):1399-402. PubMed ID: 17493468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of bifurcation lesions after implantation of drug-eluting stents with the "mini-crush technique".
    Galassi AR; Colombo A; Buchbinder M; Grasso C; Tomasello SD; Ussia GP; Tamburino C
    Catheter Cardiovasc Interv; 2007 Jun; 69(7):976-83. PubMed ID: 17295334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
    Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK
    J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year (mid-term) results for unprotected left main coronary artery percutaneous interventions with drug-eluting stents.
    Yarkoni A; Brodsky A; Sabapathy R; Pershad A
    Indian Heart J; 2008; 60(3):195-9. PubMed ID: 19240306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
    Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
    Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus 2-year clinical outcomes of the DES-DIABETES trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Hong MK; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
    J Am Coll Cardiol; 2009 Mar; 53(9):812-3. PubMed ID: 19245976
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease.
    Dobesh PP; Stacy ZA; Ansara AJ; Enders JM
    Pharmacotherapy; 2004 Nov; 24(11):1554-77. PubMed ID: 15537561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting stent update 2007: part III: Technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and multivessel disease).
    Colombo A; Chieffo A
    Circulation; 2007 Sep; 116(12):1424-32. PubMed ID: 17875983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.